Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the Multidrug-resistant Tuberculosis Pandemic; an Open Label Phase I Clinical Trial of the Therapeutic TB H56:IC31 Vaccine and Cyclooxygenase-inhibitors
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Etoricoxib (Primary) ; H56IC (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Acronyms TBCOX2
- 16 Oct 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated
- 06 Dec 2016 Planned End Date changed from 1 Oct 2018 to 1 Dec 2018.